Arctic Bioscience AS (OSL:ABS)

Norway · Delayed Price · Currency is NOK

3.200

-0.250 (-7.25%)

Mar 4, 2026, 11:34 AM CET

-32.77% (1Y)

Market Cap	93.00M
Revenue (ttm)	45.90M
Net Income (ttm)	-43.36M
Shares Out	26.96M
EPS (ttm)	-1.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,129
Average Volume	8,420
Open	3.200
Previous Close	3.450
Day's Range	3.200 - 3.400
52-Week Range	2.500 - 7.450
Beta	1.27
RSI	53.84
Earnings Date	Feb 26, 2026

About Arctic Bioscience AS

Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis. It also sells nutraceuticals as intermediary and finished goods products under the ROMEGA brand name. Arctic Bioscience AS was incorporated in 2011 and is headquartered in Ørsta, Norway. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2011

Employees 22

Stock Exchange Oslo Børs

Ticker Symbol ABS

Full Company Profile

Financial Performance

In 2024, Arctic Bioscience AS's revenue was 44.40 million, an increase of 31.55% compared to the previous year's 33.76 million. Losses were -47.93 million, 5.31% more than in 2023.

Financial Statements

News

There is no news available yet.